Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
08:00am, Wednesday, 16'th Apr 2025
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today announced that after three weeks of engagement, including a timeline extension, Ayrmid
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps
11:24am, Monday, 31'st Mar 2025
Bluebird Bio, Inc. BLUE received an unsolicited, non-binding written proposal from Ayrmid Ltd. on Friday.
Bluebird bio receives non-binding bid for up to $110.5 million
05:43pm, Friday, 28'th Mar 2025
Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.
Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update
05:06pm, Friday, 28'th Mar 2025
Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million.
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
04:15pm, Friday, 28'th Mar 2025
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal (the “Ayrmid Proposal”) from Ayrm
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates
07:25pm, Thursday, 27'th Mar 2025
Bluebird Bio (BLUE) came out with a quarterly loss of $23.74 per share versus the Zacks Consensus Estimate of a loss of $6.60. This compares to loss of $15.60 per share a year ago.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bluebird Bio, Inc. - BLUE
10:00am, Wednesday, 19'th Mar 2025
NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
03:03pm, Monday, 17'th Mar 2025
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
10:00am, Saturday, 15'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of b
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
02:00pm, Thursday, 13'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
PHILADELPHIA, PA / ACCESS Newswire / March 12, 2025 / Kehoe Law Firm, P.C. continues its investigation on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness of the p
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
12:19pm, Tuesday, 11'th Mar 2025
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
10:00am, Sunday, 09'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
10:00am, Friday, 07'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
